ZimVie Confirms Finalization of Acquisition by ARCHIMED

Written by Emily J. Thompson, Senior Investment Analyst

ZIMV%

Source: Newsfilter

Updated: Oct 20 2025

0mins

Source: Newsfilter

Acquisition Announcement: ARCHIMED has completed its acquisition of ZimVie Inc., a leader in the dental implant market, with ZimVie stockholders receiving $19.00 per share in cash. Following the acquisition, ZimVie's stock will no longer be traded on NASDAQ.
Strategic Partnership: ARCHIMED aims to accelerate ZimVie's growth by leveraging its innovation and strong clinical heritage, aligning with ARCHIMED's mission to support world-class healthcare companies.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ZimVie Confirms Finalization of Acquisition by ARCHIMED

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Amazon vs. Walmart: A Battle of Growth and Logistics

Warren Buffett Recommends Vanguard ETF Portfolio: 90% in S&P 500

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch